Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Ultragenyx Pharmaceutical (NASDAQ: RARE), a biopharmaceutical company specializing in rare and ultra-rare disease therapies, has announced an inducement grant of 48,561 restricted stock units to 17 newly hired non-executive officers. The grants were approved by the company's compensation committee under the Ultragenyx Employment Inducement Plan on September 16, 2025.

The restricted stock units feature a four-year vesting schedule, with 25% of shares vesting annually on the grant date anniversary, contingent on continued employment. This grant complies with Nasdaq Listing Rule 5635(c)(4) for employment inducement awards.

[]

News Market Reaction

+4.76%

1 alert

+4.76% News Effect

On the day this news was published, RARE gained 4.76%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

NOVATO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 48,561 restricted stock units of the company’s common stock to 17 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of September 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.

About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.

Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370

FAQ

What type of stock compensation did Ultragenyx (RARE) grant to new employees in September 2025?

Ultragenyx granted 48,561 restricted stock units to 17 newly hired non-executive officers under the Ultragenyx Employment Inducement Plan.

What is the vesting schedule for Ultragenyx's (RARE) September 2025 restricted stock units?

The restricted stock units vest over four years, with 25% of shares vesting on each anniversary of the September 16, 2025 grant date.

How many new non-executive officers received Ultragenyx (RARE) stock grants in September 2025?

17 newly hired non-executive officers received restricted stock unit grants from Ultragenyx.

Under which Nasdaq rule did Ultragenyx (RARE) issue the September 2025 inducement grants?

The grants were issued in accordance with Nasdaq Listing Rule 5635(c)(4), which governs employment inducement awards.